Abstract
3-(4-Piperidinyl)-5-arylpyrazoles, such as 1, were selective for the cloned human dopamine D4 receptor (hD4), but also showed affinity at voltage sensitive calcium, sodium and potassium ion channels. A combination of substituent changes to reduce the basicity of the piperidine nitrogen and conformational restriction to give 4,5-dihydro-1H-benzo[g]indazoles reduced this ion channel affinity at the expense of selectivity for hD4 over other dopamine receptors. Incorporation of piperazine into the 4,5-dihydro-1H-benzo[g]indazoles in place of piperidine gave a novel series of high affinity, selective, orally bioavailable hD4 ligands, such as 16, with improved selectivity over ion channels.
MeSH terms
-
Administration, Oral
-
Animals
-
Biological Availability
-
CHO Cells
-
Calcium Channels / metabolism
-
Cell Line
-
Cerebral Cortex / metabolism
-
Cricetinae
-
Humans
-
Indazoles / chemical synthesis*
-
Indazoles / chemistry
-
Indazoles / metabolism
-
Indazoles / pharmacokinetics
-
Ion Channel Gating
-
Ion Channels / metabolism*
-
Ligands
-
Muscle, Skeletal / metabolism
-
Potassium Channels / metabolism
-
Rabbits
-
Rats
-
Receptors, Dopamine D2 / biosynthesis
-
Receptors, Dopamine D2 / metabolism*
-
Receptors, Dopamine D4
-
Recombinant Proteins / biosynthesis
-
Recombinant Proteins / metabolism
-
Sodium Channels / metabolism
-
Structure-Activity Relationship
Substances
-
3-(4-(2-(2-chlorophenyl)ethyl)-1-piperazinyl)-4,5-dihydro-1H-benzo(g)indazole
-
Calcium Channels
-
DRD4 protein, human
-
Drd4 protein, rat
-
Indazoles
-
Ion Channels
-
Ligands
-
Potassium Channels
-
Receptors, Dopamine D2
-
Recombinant Proteins
-
Sodium Channels
-
Receptors, Dopamine D4